GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Operating Margin %

NKGN (NKGen Biotech) Operating Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. NKGen Biotech's Operating Income for the three months ended in Jun. 2024 was $-7.46 Mil. NKGen Biotech's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, NKGen Biotech's Operating Margin % for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for NKGen Biotech's Operating Margin % or its related term are showing as below:


NKGN's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -162.31
* Ranked among companies with meaningful Operating Margin % only.

NKGen Biotech's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

NKGen Biotech's Operating Income for the three months ended in Jun. 2024 was $-7.46 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was $-31.41 Mil.


NKGen Biotech Operating Margin % Historical Data

The historical data trend for NKGen Biotech's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Operating Margin % Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Operating Margin %
-5,131.69 -31,618.18 -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Operating Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of NKGen Biotech's Operating Margin %

For the Biotechnology subindustry, NKGen Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NKGen Biotech's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Operating Margin % distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Operating Margin % falls into.



NKGen Biotech Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

NKGen Biotech's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-29.746 / 0
= %

NKGen Biotech's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=-7.457 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NKGen Biotech  (NAS:NKGN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


NKGen Biotech Operating Margin % Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech Business Description

Traded in Other Exchanges
N/A
Address
3001 Daimler Street, Santa Ana, CA, USA, 92705
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

NKGen Biotech Headlines

From GuruFocus